Source-grounded facts extracted from Kiniksa Pharmaceuticals International, plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of compensation of named executive officers at the 2026-05-29 meeting.
“Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company’s named executive officers.”
Kiniksa Pharmaceuticals International, plc shareholders approved Approve UK Statutory Directors’ Remuneration Policy at the 2026-05-29 meeting.
“Proposal 7 - To approve the Company’s UK Statutory Directors’ Remuneration Policy.”
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of UK Statutory Directors’ Annual Remuneration Report for period ended December 31, 2025 at the 2026-05-29 meeting.
“Proposal 6 - To approve, on an advisory non-binding basis, the Company’s UK Statutory Directors’ Annual Remuneration Report for the period ended December 31, 2025.”
Kiniksa Pharmaceuticals International, plc shareholders approved Receive UK statutory annual account and report for period ended December 31, 2025 at the 2026-05-29 meeting.
“Proposal 5 - To receive the Company’s UK statutory annual account and report for the period ended December 31, 2025.”
Kiniksa Pharmaceuticals International, plc shareholders approved Authorize board of directors, through audit committee, to determine PwC’s remuneration as UK statutory auditors at the 2026-05-29 meeting.
“Proposal 4 - To authorize the Company’s board of directors, through its audit committee, to determine PwC’s remuneration in its capacity as the Company’s UK statutory auditors until the close of its next Annual Meeting of Shareholders.”
Kiniksa Pharmaceuticals International, plc shareholders approved Ratify appointment of PwC as US independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-29 meeting.
“Proposal 3 - To ratify the appointment of PwC as the Company’s US independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as UK statutory auditors at the 2026-05-29 meeting.
“Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s UK statutory auditors until the close of the Company’s next Annual Meeting.”
Kiniksa Pharmaceuticals International, plc shareholders approved Re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors at the 2026-05-29 meeting.
“Proposal 1 - The re-election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve on the Board of Directors until the 2029 Annual Meeting of Shareholders”
Kiniksa Pharmaceuticals International, plc entered into Deed with Baker Bros. Advisors LP, on behalf of each of Baker Brothers Life Sciences, L.P. and 667, L.P. (the "Shareholders") (effective 2026-05-21).
“On May 21, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) entered into a deed of waiver (the “Deed”) with Baker Bros. Advisors LP, on behalf of each of Baker Brothers Life Sciences, L.P. and 667, L.P. (the “Shareholders”), pursuant to which the Shareholders waived their rights to convert any of their Class A1 or Class B1 ordinary shares into Class A or Class B ordinary shares (“Conversion Rights”) if, immediately prior to or following such conversion, the Shareholders would beneficially own more than 49.9% of the Company’s outstanding voting rights.”
Eben Tessari was appointed as special advisor to the Company's Science and Research Committee at Kiniksa Pharmaceuticals International, plc.
“Pursuant to a Consulting Agreement (the "Consulting Agreement") between Mr. Tessari and the Company, which will be effective as of May 15, 2026, Mr. Tessari will: (i) provide services to the Company related to strategic and operational matters and (ii) serve as a special advisor to the Company's Science and Research Committee (together, the "Services").”
Eben Tessari resigned as Chief Strategy Officer at Kiniksa Pharmaceuticals International, plc.
“On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the "Company") of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry.”
Kiniksa Pharmaceuticals International, plc reported the quarter ended March 31, 2026 results: revenue $214.3 million, net income $22.6 million. Guidance raised.
“--- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected”
Kiniksa Pharmaceuticals International, plc announced a restructuring with charges of approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses affecting Phase 2b clinical trial of abiprubart in Sjögren’s Disease.
“completion of winddown activities expected to occur by the end of 2025. As a result of the termination of the Phase 2b clinical trial, the Company has incurred approximately $19 million in expenses and expects to record approximately $14 million to $17 million in additional expenses, almost entirely consisting of expenses related to contract termination costs”
M. Cantey Boyd was appointed as Director at Kiniksa Pharmaceuticals International, plc.
“the appointment of M. Cantey Boyd, age 44, to the Board to fill the vacancy created thereby”
Kiniksa Pharmaceuticals International, plc reported first quarter 2024 results: revenue Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023., net income Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter. Guidance raised.
“On April 23, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended March 31, 2024.”
Kiniksa Pharmaceuticals International, plc reported fourth quarter and full-year 2023 results: revenue $71.2 million and $233.2 million.
“ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million”
Kiniksa Pharmaceuticals International, plc reported financial results for the fiscal year ended December 31, 2023.
“On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023.”
Kiniksa Pharmaceuticals International, plc reported the fourth quarter and full year 2023 results: revenue ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud. Guidance initiated.
“On January 4, 2024, Kiniksa Pharmaceuticals, Ltd. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, that (i) its preliminary year-end 2023 cash, cash equivalents and short-term investments of $206.3 million (unaudited) are expected to fund its current operating plan into at least 2027 and (ii) ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited).”
Kiniksa Pharmaceuticals International, plc reported financial results for third quarter 2023.
“On October 31, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended September 30, 2023.”
Kiniksa Pharmaceuticals International, plc reported quarter ended June 30, 2023 results: revenue $71.5 million, net income $15.0 million. Guidance raised.
“Financial Results • Total revenue for the second quarter of 2023 was $71.5 million, compared to $27.0 million for the second quarter of 2022. - Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue and $0.0 million in license and collaboration revenue for the second quarter of 2022. • Total operating expenses for the second quarter of 2023 were $74.6 million, compared to $46.3 million for the second quarter of 2022. - Total operating expenses for the second quarter of 2023 included $6.5 million in non-cash, share-based compensation expense, compared to $6.7 million for the second quarter of 2022. • Net income for the second quarter of 2023 was $15.0 million, compared to a net loss of $20.0 million for the second quarter of 2022. - Net income for the second quarter of 2023 included a $16.2 million tax benefit primarily due to the”
Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of the compensation of named executive officers as disclosed in the proxy statement at the 2023-06-06 meeting.
“Proposal 3 – The approval, on a non-binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the applicable compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,423,385 1,270,222 380,052 3,132,968”
Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as auditor and ratification of their appointment for fiscal year 2023 at the 2023-06-06 meeting.
“Proposal 2 – The (a) appointment of PricewaterhouseCoopers LLP as the Company’s auditor until the close of the Company’s next Annual Meeting of Shareholders, (b) delegation to the Company’s Board of Directors, through the Audit Committee of the Board of Directors, of the authority to set the auditor’s remuneration for such period, and (c) ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,804,941 23,637 378,049 0”
Kiniksa Pharmaceuticals International, plc shareholders approved Election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting at the 2023-06-06 meeting.
“Proposal 1 – The election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified. Nominee Votes FOR Votes WITHHELD Broker Non-Votes Stephen R. Biggar 30,959,772 11,113,887 3,132,968 G. Bradley Cole 40,974,400 1,099,259 3,132,968 Barry D. Quart 40,953,831 1,119,828 3,132,968”
Kiniksa Pharmaceuticals International, plc reported first quarter 2023 results: revenue $48.3 million, net income $12.3 million. Guidance raised.
“diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated. Financial Results · Total revenue for the first quarter of 2023 was $48.3 million, compared to $32.2 million for the first quarter of 2022. - Total revenue for the first quarter of 2023 included $42.7 million in ARCALYST net product revenue and $5.7 million in”
Kiniksa Pharmaceuticals International, plc reported the fiscal year ended December 31, 2022 results: revenue Total revenue for the full-year 2022 was $220.2 million, net income Net income for the full-year 2022 was $183.4 million. Guidance reaffirmed.
“On February 28, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2022.”
Kiniksa Pharmaceuticals International, plc reported the full year 2022 results: revenue $122.5 million.
“ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).”
Kiniksa Pharmaceuticals International, plc reported the fourth quarter of 2022 results: revenue $39.9 million.
“ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).”
Kiniksa Pharmaceuticals International, plc reported Third Quarter 2022 results: revenue $99.1 million, net income $224.1 million.
“Total revenue for the third quarter of 2022 was $99.1 million, compared to $12.1 million for the third quarter of 2021. - Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST net product revenue and $65.7 million in license and collaboration revenue from the vixarelimab global license agreement with Genentech. Kiniksa did not report license and collaboration revenue in the third quarter of 2021. · Total operating expenses for the third quarter of 2022 were $52.7 million, compared to $42.8 million for the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $4.6 million in collaboration expense. Kiniksa did not report collaboration expense in the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $6.0 million of non-cash, share-based compensation expense, compared to $6.2 million for third quarter of 2021. · Net income for the third quarter of 2022 was $224.1 million, compared to a net lo”
Eben Tessari was appointed as SVP, Chief Operating Officer at Kiniksa Pharmaceuticals International, plc.
“Effective January 3, 2022, the Board of Directors (the “Board”) of Kiniksa Pharmaceuticals, Ltd. (the “Company”) appointed Eben Tessari as the Company’s SVP, Chief Operating Officer and principal operating officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.